Neurogene Inc. (NASDAQ:NGNE - Free Report) - Research analysts at William Blair increased their Q2 2024 EPS estimates for Neurogene in a note issued to investors on Tuesday, May 7th. William Blair analyst S. Corwin now anticipates that the company will earn ($0.89) per share for the quarter, up from their prior forecast of ($1.15). William Blair has a "Outperform" rating and a $61.00 price target on the stock. The consensus estimate for Neurogene's current full-year earnings is ($3.98) per share. William Blair also issued estimates for Neurogene's Q3 2024 earnings at ($0.94) EPS, Q4 2024 earnings at ($0.82) EPS and FY2024 earnings at ($3.99) EPS.
NGNE has been the topic of several other research reports. HC Wainwright reissued a "buy" rating and set a $55.00 price objective on shares of Neurogene in a research note on Friday, May 3rd. Leerink Partnrs restated an "outperform" rating on shares of Neurogene in a research note on Monday, April 29th. Finally, SVB Leerink began coverage on Neurogene in a research note on Monday, April 29th. They set an "outperform" rating and a $46.00 price objective for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Neurogene currently has an average rating of "Buy" and an average target price of $48.25.
View Our Latest Report on NGNE
Neurogene Price Performance
Shares of NASDAQ:NGNE traded down $0.71 during trading on Friday, hitting $32.50. The stock had a trading volume of 28,093 shares, compared to its average volume of 119,871. The company has a market cap of $418.28 million, a P/E ratio of -2.68 and a beta of 1.36. The company has a fifty day moving average of $38.48. Neurogene has a 12 month low of $12.20 and a 12 month high of $53.00.
Hedge Funds Weigh In On Neurogene
A number of hedge funds have recently added to or reduced their stakes in NGNE. SG Americas Securities LLC bought a new stake in shares of Neurogene in the 1st quarter worth $120,000. Privium Fund Management UK Ltd purchased a new stake in shares of Neurogene during the first quarter valued at $274,000. BML Capital Management LLC bought a new stake in Neurogene in the 4th quarter worth about $478,000. Avidity Partners Management LP purchased a new position in shares of Neurogene during the fourth quarter valued at approximately $9,036,000. Finally, Great Point Partners LLC purchased a new stake in Neurogene during the 4th quarter valued at $19,268,000. 52.37% of the stock is currently owned by hedge funds and other institutional investors.
About Neurogene
(
Get Free Report)
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Featured Stories
Before you consider Neurogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.
While Neurogene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
